JMC Investment Acquired Equity Stake in SiO2
December 14, 2015
JMC Investment LLC (JMC) is pleased to announce it has acquired an equity stake in SiO2 Medical Products (SiO2), a supplier of innovative solutions to the pharmaceutical industry geared toward life science research and development, with a special expertise in biologic drugs. Working with industry leaders, SiO2 utilizes a proprietary and patented low pressure plasma enhanced chemical vapor deposition (PECVD) process to address critical needs in parenteral containers and laboratory testing.
Jean-Marie Painvin, Founder & CEO of JMC said, “The breakthrough technology developed by SiO2 is truly innovative and addresses an important need in the development and handling of biologics and complex high protein drugs. It is very exciting to part of this cutting-edge technology with a company that is anticipating the needs of the future.”
Mr. Abrams, CEO of SiO2, said that, “Having a partner like JMC with a strong precision manufacturing background and expertise in growing a global business will perfectly complement our growth vision.”
About SiO2 Medical Products
SiO2 Medical Products is a privately held company headquartered in Auburn, AL. Using advanced material science, SiO2 has developed a line of containers designed specifically for the parenteral market to offer improved performance and consistency over existing containers. SiO's syringes, vials, cartridges, and other custom containers are precision-molded from medical-grade plastics and have a thin, transparent, silicon-oxide barrier coating system deposited on the interior surfaces.
For more information, please visit www.sio2med.com.